These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 3482131

  • 1. [Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside].
    Patterson D, Kravtsova VM, Petrova EM, Zabelina TS, Balaian LN.
    Ter Arkh; 1987; 59(12):81-6. PubMed ID: 3482131
    [Abstract] [Full Text] [Related]

  • 2. [Results of induction therapy in newly diagnosed acute myeloid leukemias in study 911 at the Institute of Hematology and Blood Transfusion].
    Lemez P, Vítek A, Jelínek J, Lukásová M, Palecek A, Sajdová J, Jedlicková A, Vorlová Z.
    Vnitr Lek; 1995 Jan; 41(1):34-9. PubMed ID: 7716891
    [Abstract] [Full Text] [Related]

  • 3. Seven day cytosine arabinoside administered subcutaneously plus daunorubicin for remission induction in AML.
    Holowiecki J, Rudzka E, Jarczok K, Holowiecka B, Krawczyk M, Duraj M, Japa J.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983 Jan; 110(6):792-7. PubMed ID: 6200390
    [Abstract] [Full Text] [Related]

  • 4. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J, Mathé G, Hayat M.
    Bull Cancer; 1974 Jan; 61(3):411-8. PubMed ID: 4533741
    [No Abstract] [Full Text] [Related]

  • 5. [Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin].
    Lemez P, Gáliková J, Haas T.
    Vnitr Lek; 1999 Jun; 45(6):342-6. PubMed ID: 11045169
    [Abstract] [Full Text] [Related]

  • 6. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I, Hara M, Ohmoto E, Oda Y, Endo Y, Fujimoto S, Uchida K, Takaoka K, Watanabe S, Lai M, Kohi F, Kitajima K, Kimura I, Sanada H, Tokioka M, Adachi T, Yorimitsu S.
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
    Cripe LD, Rader K, Tallman MS, Gordon MS, Paietta E, Bennett J, Neuberg D, Litzow MR, O'brien TE, Rowe JM.
    Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
    [Abstract] [Full Text] [Related]

  • 8. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR, Velez-Garcia E, Omura G, Raney M.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract] [Full Text] [Related]

  • 9. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [Abstract] [Full Text] [Related]

  • 10. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 17. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y, Sampi K, Kuraishi Y, Okabe K, Tamura K, Mizoguchi H, Saito H, Masaoka T, Ogawa M.
    Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
    [Abstract] [Full Text] [Related]

  • 18. [Comparative analysis of 3 therapeutic regimens based on the combination of an anthracycline and cytosine arabinoside for remission induction in myeloblastic leukemia].
    Sanz MA, Lorenzo JI, Sanz GF, Martín Aragonés G, Rafecas FJ, Martínez JA, Gomis F.
    Sangre (Barc); 1988 Dec; 33(6):497-504. PubMed ID: 3247626
    [No Abstract] [Full Text] [Related]

  • 19. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
    Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R.
    Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
    [Abstract] [Full Text] [Related]

  • 20. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.